COMMUNIQUÉS West-GlobeNewswire

Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
27/05/2025
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: [...]
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
27/05/2025
SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that [...]
Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
27/05/2025
BURLINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric [...]
Precision Optics to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
27/05/2025
GARDNER, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]
Dentsply Sirona Declares Quarterly Cash Dividend
27/05/2025
CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of [...]
Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025
27/05/2025
SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast [...]
BioAge Labs to Present at Upcoming Investor Conferences
27/05/2025
EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by [...]
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
27/05/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
27/05/2025
PRINCETON, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 2025 Jefferies Global [...]
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
27/05/2025
TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming investor [...]
Galapagos Creates New Subscription Right Plan
27/05/2025
Mechelen, Belgium; May 27, 2025, 22:30 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 925,000 subscription rights under a new subscription [...]
INVO Fertility to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
27/05/2025
SARASOTA, Fla., May 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through [...]
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
27/05/2025
Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac disease [...]
Extendicare Announces Voting Results for its 2025 Annual and Special Meeting of Shareholders
27/05/2025
MARKHAM, Ontario, May 27, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today announced the results of matters voted on at its annual and special meeting of shareholders held on [...]
Aptose Announces Results from Annual and Special Meeting of Shareholders
27/05/2025
SAN DIEGO and TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple [...]
CARBIOS signe ses premiers contrats de vente de PET biorecyclé avec deux leaders mondiaux de la cosmétique
27/05/2025
CARBIOS a signé deux contrats commerciaux pluriannuels de PET biorecyclé issu de l’usine de Longlaville, avec L’ORÉAL et L’Occitane en Provence et réalise une avancée dans l’exécution de sa stratégie pour sa future [...]
CARBIOS signs its first biorecycled PET sales contracts with two global cosmetics leaders
27/05/2025
CARBIOS has signed two multi-year commercial contracts for biorecycled PET from its Longlaville plant, with L'ORÉAL and L'Occitane en Provence, and has moved forward with the execution of this future plant’s strategy [...]
Nexzen Extracts Emerges as a Premium Name in Hemp-Derived Wellness Products
27/05/2025
Nexzen Extracts, a rising brand in the hemp and cannabis wellness space, has officially announced its expansion into the national market with a product line focused on purity, potency, and plant-based innovation [...]
23andMe Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
27/05/2025
SAN FRANCISCO, May 27, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced its intention to file a Form 25 [...]

Pages